Interpace Biosciences Q2 revenue falls despite growth in thyroid business

Interpace Biosciences

10/08/2026 21:47

Overview
U.S. thyroid diagnostics firm's Q2 revenue fell 1% yr/yr, up 9% on thyroid-only basis
Company posted net income from continuing operations, reversing prior-year loss
Gross margin expanded and adjusted EBITDA improved following shift to thyroid-only business

Outlook
Company expects continued margin expansion through the remainder of 2026
Interpace does not expect pancreatic cancer program to contribute revenue in 2026

Result Drivers
THYROID REVENUE GROWTH - Co said 9% yr/yr increase in thyroid revenue and 6% rise in thyroid test volume supported results
OPERATIONAL EFFICIENCY - Co attributed margin expansion to laboratory automation and AI-enabled productivity initiatives
IMPROVED COMMERCIAL EXECUTION - Co cited increased average revenue per test, improved days sales outstanding, and faster turnaround times

Company press release: ID:nGNX5KNMS2

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$9.13 mln
 
Q2 Net Income
 
$158,000
 
Q2 Gross Profit
 
$5.65 mln
 
Q2 Net Income from Continuing Operations
 
$266,000
 
Q2 Operating Expenses
 
$5.33 mln
 
Q2 Operating Income
 
$321,000
 

Reuters Recommended Reads
Aug 9 - RadNet raises outlook as Q2 revenue jumps 25%, adjusted EPS beats estimates 
Aug 10 - Bionano Genomics Q2 revenue rises on increased clinical adoption
Aug 10 - Quanterix Q2 revenue rises 34% but cuts 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)